756 related articles for article (PubMed ID: 21787319)
1. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
Hölscher C
Biochem Soc Trans; 2011 Aug; 39(4):891-7. PubMed ID: 21787319
[TBL] [Abstract][Full Text] [Related]
2. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease?
Hölscher C; Li L
Neurobiol Aging; 2010 Sep; 31(9):1495-502. PubMed ID: 18930564
[TBL] [Abstract][Full Text] [Related]
3. The role of GLP-1 in neuronal activity and neurodegeneration.
Hölscher C
Vitam Horm; 2010; 84():331-54. PubMed ID: 21094907
[TBL] [Abstract][Full Text] [Related]
4. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease.
Duffy AM; Hölscher C
Neuroscience; 2013 Jan; 228():294-300. PubMed ID: 23103794
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
[TBL] [Abstract][Full Text] [Related]
6. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
Bak AM; Egefjord L; Gejl M; Steffensen C; Stecher CW; Smidt K; Brock B; Rungby J
Expert Opin Ther Targets; 2011 Oct; 15(10):1153-62. PubMed ID: 21749267
[TBL] [Abstract][Full Text] [Related]
7. [Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease].
Wang XH; Yang W; Qi JS
Sheng Li Xue Bao; 2010 Oct; 62(5):398-406. PubMed ID: 20945041
[TBL] [Abstract][Full Text] [Related]
8. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.
Abbas T; Faivre E; Hölscher C
Behav Brain Res; 2009 Dec; 205(1):265-71. PubMed ID: 19573562
[TBL] [Abstract][Full Text] [Related]
9. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease.
Hölscher C
Alzheimers Dement; 2014 Feb; 10(1 Suppl):S47-54. PubMed ID: 24529525
[TBL] [Abstract][Full Text] [Related]
10. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.
Hölscher C
Biochem Soc Trans; 2014 Apr; 42(2):593-9. PubMed ID: 24646283
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease.
Tai J; Liu W; Li Y; Li L; Hölscher C
Brain Res; 2018 Jan; 1678():64-74. PubMed ID: 29050859
[TBL] [Abstract][Full Text] [Related]
12. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
Hölscher C
Sheng Li Xue Bao; 2014 Oct; 66(5):497-510. PubMed ID: 25331995
[TBL] [Abstract][Full Text] [Related]
13. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
[TBL] [Abstract][Full Text] [Related]
14. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
Holscher C
Recent Pat CNS Drug Discov; 2010 Jun; 5(2):109-17. PubMed ID: 20337586
[TBL] [Abstract][Full Text] [Related]
15. New animal models of Alzheimer's disease that display insulin desensitization in the brain.
Gao C; Liu Y; Li L; Hölscher C
Rev Neurosci; 2013; 24(6):607-15. PubMed ID: 24259244
[TBL] [Abstract][Full Text] [Related]
16. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Nov; 86():241-58. PubMed ID: 25107586
[TBL] [Abstract][Full Text] [Related]
17. Brain insulin resistance: role in neurodegenerative disease and potential for targeting.
Hölscher C
Expert Opin Investig Drugs; 2020 Apr; 29(4):333-348. PubMed ID: 32175781
[No Abstract] [Full Text] [Related]
18. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.
Hölscher C
CNS Drugs; 2012 Oct; 26(10):871-82. PubMed ID: 22938097
[TBL] [Abstract][Full Text] [Related]
19. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
Hölscher C
J Endocrinol; 2014 Apr; 221(1):T31-41. PubMed ID: 23999914
[TBL] [Abstract][Full Text] [Related]
20. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Chen Z; Zhong C
Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
